Retatrutide is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors currently being studied as an investigational medicine for obesity and type 2 diabetes (phase 2 data published in the New England Journal of Medicine, 2023)
These drugs were approved by the U.S
This medication reduces hunger, so if youre busy and skip meals, nausea can kick in Eating every four to five hours helps prevent your stomach from being empty. Semaglutide (Wegovy) is approved by the US Food and Drug Administration (FDA) for weight loss and is the most accessible
When GLP-1 receptors are activated, four things happen: appetite is suppressed through signals in the hypothalamus and brainstem, gastric emptying slows (keeping you full longer), glucose-dependent insulin release is enhanced, and inappropriate post-meal glucagon release is suppressed
Drawing 10 units versus 12 units is a 20% dose difference, which is significant when you are trying to maintain a precise starting dose
Rapid weight loss, a common outcome with GLP-1 drugs, can trigger telogen effluvium, causing more hair follicles to enter the resting phase where shedding occurs
